{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T02:45:42Z","timestamp":1780713942523,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jdin.2024.02.016","type":"journal-article","created":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T02:05:32Z","timestamp":1709949932000},"page":"244-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Diabetes and obesity burden and improvements in cardiometabolic parameters in patients with psoriasis or psoriatic arthritis receiving apremilast in a real-world setting"],"prefix":"10.1016","volume":"16","author":[{"given":"Cristi","family":"Cavanaugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Orroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam","family":"Kumparatana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Klyachkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Colgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Cordey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdin.2024.02.016_bib1","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/jid.2010.103","article-title":"Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions","volume":"130","author":"Davidovici","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jdin.2024.02.016_bib2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/rheumatology\/ket343","article-title":"Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study","volume":"53","author":"Dubreuil","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jdin.2024.02.016_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3899\/jrheum.120237","article-title":"Metabolic syndrome in patients with psoriatic disease","volume":"89","author":"Gelfand","year":"2012","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.jdin.2024.02.016_bib4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/archdermatol.2010.370","article-title":"Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006","volume":"147","author":"Love","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jdin.2024.02.016_bib5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jdin.2024.02.016_bib6","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2024.02.016_bib7","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jdin.2024.02.016_bib8","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard-2023-224148","article-title":"EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis","volume":"82","author":"Zabotti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jdin.2024.02.016_bib9","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database","volume":"31","author":"Mehta","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdin.2024.02.016_bib10","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jdin.2024.02.016_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11883-021-00963-y","article-title":"Psoriasis and cardiovascular disease: novel mechanisms and evolving therapeutics","volume":"23","author":"Weber","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jdin.2024.02.016_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/OARRR.S347797","article-title":"Metabolic syndrome and its components in psoriatic arthritis","volume":"14","author":"Aljohani","year":"2022","journal-title":"Open Access Rheumatol"},{"key":"10.1016\/j.jdin.2024.02.016_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.det.2014.09.002","article-title":"The immunopathogenesis of psoriasis","volume":"33","author":"Kim","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jdin.2024.02.016_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ncprheum0987","article-title":"New insights into the pathogenesis and genetics of psoriatic arthritis","volume":"5","author":"Nograles","year":"2009","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.jdin.2024.02.016_bib15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jaad.2014.02.012","article-title":"Diet and psoriasis, part I: impact of weight loss interventions","volume":"71","author":"Debbaneh","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2024.02.016_bib16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2458-9-88","article-title":"The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis","volume":"9","author":"Guh","year":"2009","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.jdin.2024.02.016_bib17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaad.2017.10.050","article-title":"Psoriasis and the risk of diabetes: a prospective population-based cohort study","volume":"78","author":"Wan","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2024.02.016_bib18","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3899\/jrheum.140021","article-title":"High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease","volume":"41","author":"Haroon","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jdin.2024.02.016_bib19","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","article-title":"Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study","volume":"41","author":"Pirro","year":"2021","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jdin.2024.02.016_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/obr.12385","article-title":"Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders","volume":"17","author":"Wu","year":"2016","journal-title":"Obes Rev"},{"key":"10.1016\/j.jdin.2024.02.016_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/906349","article-title":"The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1)","volume":"2015","author":"Schafer","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jdin.2024.02.016_bib22","doi-asserted-by":"crossref","first-page":"AB151","DOI":"10.1016\/j.jaad.2018.05.625","article-title":"Hemoglobin A1c and weight changes with apremilast in patients with psoriasis and psoriatic arthritis: pooled laboratory analysis of the phase 3 ESTEEM and PALACE trials","volume":"79","author":"Puig","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2024.02.016_bib23","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1001\/jamadermatol.2022.3862","article-title":"Association of apremilast with vascular inflammation and cardiometabolic function in patients with psoriasis: the VIP-A phase 4, open-label, nonrandomized clinical trial","volume":"158","author":"Gelfand","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jdin.2024.02.016_bib24","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3899\/jrheum.140647","article-title":"Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis","volume":"42","author":"Kavanaugh","year":"2015","journal-title":"J Rheumatol"},{"issue":"3 suppl","key":"10.1016\/j.jdin.2024.02.016_bib25","doi-asserted-by":"crossref","first-page":"AB158","DOI":"10.1016\/j.jaad.2023.07.635","article-title":"Efficacy of apremilast in patients with moderate to severe plaque psoriasis across weight and BMI subgroups: analysis from ESTEEM 1 and ESTEEM 2","volume":"89","author":"Langley","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2024.02.016_bib26","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/joim.13447","article-title":"The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast","volume":"291","author":"Arias de la Rosa","year":"2022","journal-title":"J Intern Med"},{"key":"10.1016\/j.jdin.2024.02.016_bib27","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/rheumatology\/keab474","article-title":"Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-results of the Immune Metabolic Associations in Psoriatic Arthritis study","volume":"61","author":"Ferguson","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jdin.2024.02.016_bib28","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/1346-8138.15293","article-title":"Real life experience of apremilast in psoriasis and arthritis psoriatic patients: preliminary results on metabolic biomarkers","volume":"47","author":"Mazzilli","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.jdin.2024.02.016_bib29","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40257-023-00783-7","article-title":"Apremilast long-term safety up to 5 years from 15 pooled randomized, placebo-controlled studies of psoriasis, psoriatic arthritis, and Beh\u00e7et's syndrome","volume":"24","author":"Mease","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jdin.2024.02.016_bib30","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1186\/s12889-021-12009-8","article-title":"The association between obesity and quality of life: a retrospective analysis of a large-scale population-based cohort study","volume":"21","author":"Stephenson","year":"2021","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.jdin.2024.02.016_bib31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4239\/wjd.v8.i4.120","article-title":"Type 2 diabetes and quality of life","volume":"8","author":"Trikkalinou","year":"2017","journal-title":"World J Diabetes"},{"key":"10.1016\/j.jdin.2024.02.016_bib32","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1016\/S2468-2667(17)30074-9","article-title":"Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe","volume":"2","author":"Kivim\u00e4ki","year":"2017","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.jdin.2024.02.016_bib33","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13075-019-1901-3","article-title":"Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis","volume":"21","author":"Kavanaugh","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"suppl 1","key":"10.1016\/j.jdin.2024.02.016_bib34","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1136\/annrheumdis-2023-eular.45","article-title":"Effects of apremilast on changes in cardiometabolic parameters by diabetes and obesity status in patients with psoriatic arthritis","volume":"82","author":"Mease","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T03:59:13Z","timestamp":1740887953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328724000373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":34,"alternative-id":["S2666328724000373"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2024.02.016","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetes and obesity burden and improvements in cardiometabolic parameters in patients with psoriasis or psoriatic arthritis receiving apremilast in a real-world setting","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2024.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}